Arbeitsgemeinschaft Gynäkologische Onkologie e.V. (AGO)
Research facility
Location:
Taufkirchen,
Germany (DE)
ISNI: -
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial (2023)
Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, et al.
Journal article
Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG) (2018)
Pfisterer J, Dean AP, Baumann K, Rau J, Harter P, Joly F, Sehouli J, et al.
Conference contribution